• 1
    Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001; 81: 741766.
  • 2
    Hutton M, McGowan E. Clearing tau pathology with abeta immunotherapy – reversible and irreversible stages revealed. Neuron 2004; 43: 293294.
  • 3
    Busciglio J, Lorenzo A, Yeh J et al. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995; 14: 879888.
  • 4
    Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631639.
  • 5
    Bantubungi K, Blum D, Cuvelier L et al. Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease. Mol Cell Neurosci 2008; 37: 454470.
  • 6
    Cho YH, Kim HS, Lee KH et al. The behavioral effect of human mesenchymal stem cell transplantation in cold brain injured rats. Acta Neurochir Suppl 2006; 99: 125132.
  • 7
    Bae JS, Furuya S, Shinoda Y et al. Neurodegeneration augments the ability of bone marrow-derived mesenchymal stem cells to fuse with Purkinje neurons in Niemann-Pick type C mice. Hum Gene Ther 2005; 16: 10061011.
  • 8
    Lee JK, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells reduce brain amyloid-beta deposition and accelerate the activation of microglia in an acutely induced Alzheimer's disease mouse model. Neurosci Lett 2009; 450: 136141.
  • 9
    Wegiel J, Wang KC, Imaki H et al. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. Neurobiol Aging 2001; 22: 4961.
  • 10
    Malm TM, Koistinaho M, Parepalo M et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzehimer mice. Neurobiol Dis 2005; 18: 134142.
  • 11
    Simard AR, Soulet D, Gowing G et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006; 49: 489502.
  • 12
    Coraci IS, Husemann J, Berman JW et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta amyloid fibrils. Am J Pathol 2002; 160: 101112.
  • 13
    El Khoury JB, Moore KJ, Means TK et al. CD36 mediates the innate host response to beta amyloid. J Exp Med 2003; 197: 16571666.
  • 14
    Meda L, Cassatella MA, Szendrei GI et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995; 374: 647650.
  • 15
    Rogers J, Strohmeyer R, Kovelowski CJ et al. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 2002; 40: 260269.
  • 16
    Chung H, Brazil MI, Soe Ttet al. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta peptide by microglial cells. J Biol Chem 1999; 274: 3230132308.
  • 17
    Ohtaki H, Ylostalo JH, Foraker JE et al. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune response. Proc Natl Acad Sci U S A 2008; 105: 1463814643.
  • 18
    Howlett DR, Richardson JC, Austin A et al. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgene. Brain Res 2004; 1017: 130136.
  • 19
    Näslund J, Haroutunian V, Mohs R et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 15711577.
  • 20
    Koistinaho M, Ort M, Cimadevilla JM et al. Specific spatial learning deficits become severe with age in beta-amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc Natl Acad Sci U S A 2001; 98: 1467514680.
  • 21
    Leissring MA, Farris W, Chang AY et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003; 40: 10871093.
  • 22
    Yan P, Hu X, Song H et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 2006; 281: 2456624574.
  • 23
    Yan SD, Chen X, Fu J et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685691.
  • 24
    El Khoury J, Hickman SE, Thomas CA et al. Microglia, scavenger receptor, and the pathogenesis of Alzheimer's disease. Neurobiol Aging 1998; 19: S81S84.
  • 25
    Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathway in aging Alzheimer's disease mice. J Neurosci 2008; 28: 83548360.
  • 26
    Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184: 6991.
  • 27
    Janelsins MC, Mastrangelo MA, Oddo S et al. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation 2005; 2: 23.
  • 28
    Gordon S. Alternative activation of macrophage. Nat Rev Immunol 2003; 3: 2335.
  • 29
    Edwards JP, Zhang X, Frauwirth KA et al. Biochemical and functional characterization of three activated macrophage population. J Leukoc Biol 2006; 80: 12981307.
  • 30
    Roberson ED, Scearce-Levie K, Palop JJ et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750754.
  • 31
    Howlett DR, Bowler K, Soden PE et al. Aβ deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease. Histol Histopathol 2008; 23: 6776.
  • 32
    Blurton-Jones M, LaFerla FM. Pathway by which Abeta facilitates tau pathology. Curr Alzheimer Res 2006; 3: 437448.
  • 33
    El Khoury J, Toft M, Hickman SE et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer's-like disease. Nat Med 2007; 13: 432438.
  • 34
    Iwata N, Tsubuki S, Takaki Y et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292: 15501552.
  • 35
    Richard KL, Filali M, Préfontaine P et al. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse of Alzheimer's disease. J Neurosci 2008; 28: 57845793.
  • 36
    Farris W, Mansourian S, Chang Yet al. Insukin-degrading enzyme regulates the levels of insulin, amyloid beta protein, the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA. 2003; 100: 41624167.
  • 37
    Yasojima K, Akiyama H, McGeer EG et al. Reduced neprilysin in high plaque areas of Alzheimer brain: A possible relationship to deficient degradation of beta-amyloid peptides. Neurosci Lett 2001; 297: 97100.
  • 38
    Boissonneault V, Filali M, Lessard M et al. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 2009; 132: 10721092.
  • 39
    Pérez A, Morelli L, Cresto JC et al. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brain. Neurochem Res 2000; 25: 247255.
  • 40
    Zhao J, Xiang Z, Haroutunian V et al. Insulin degrading enzyme activity selectivrly decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 2007; 28: 824830.
  • 41
    Walker DJ, Link J, Lue JF et al. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 2006; 79: 596610.
  • 42
    Rosenberg PB. Clinical aspects of inflammation in Alzheimer's disease. Int Rev Psychiatry 2005; 17: 503514.
  • 43
    Ponomarev ED, Maresz K, Tan Y et al. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci 2007; 27: 1071410721.
  • 44
    Iribarren P, Chen K, Hu J et al. IL-4 inhibits the expression of mouse formyl peptide receptor 2, a receptor for amyloid beta 1-42, in TNF-alpha-activated microglia. J Immunol 2005; 175: 61006106.
  • 45
    Falcone M, Rajan AJ, Bloom BR et al. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J Immunol 1998; 160: 48224830.
  • 46
    Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005; 25: 82408249.
  • 47
    Stein M, Keshav S, Harris N et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287292.
  • 48
    Butovsky O, Talpalar AE, Ben-Yaakov K et al. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol Cell Neurosci 2005; 29: 381393.
  • 49
    Zhao W, Xie W, Xiao Q et al. Protective effectives of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J Neurochem 2006; 99: 11761187.
  • 50
    Butovsky O, Koronyo-Hamaoui M, Kunis G et al. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A 2006; 103: 1178411789.
  • 51
    Oddo S, Caccamo A, Tseng B et al. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: A mechanistic link between Abeta and tau pathology. J Neurosci 2008; 28: 1216312175.
  • 52
    Oddo S, Caccamo A, Smith IF et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A Link Between Abeta And Tau Pathology J Biol Chem 2006; 281: 15991604.
  • 53
    Chen G, Chen KS, Knox J et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000; 408: 975979.
  • 54
    Schindowski K, Bretteville A, Leroy K et al. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 2006; 169: 599616.
  • 55
    Morris RG, Garrud P, Rawlins JN et al. Place navigation impaired in rats with hippocampal lesion. Nature 1982; 297: 681683.
  • 56
    Parr AM, Tator CH, Keating A. Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant 2007; 40: 609619.
  • 57
    Prockop DJ. “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther 2007; 82: 241243.
  • 58
    Munoz JR, Stoutenger BR, Robinson AP et al. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc Natl Acad Sci U S A 2005; 102: 1817118176.
  • 59
    Bae JS, Han HS, Youn DH et al. Bone marrow-derived mesenchymal stem cells promote neuronal networks with functional synaptic transmission after transplantation into mice with neurodegeneration. Stem Cells 2007; 25: 13071316.